Erasmus School of Health Policy & Management
External PhD candidate | Health Technology Assessment (HTA)
- vanschaik@eshpm.eur.nl
More information
Work
- Astrid Kramer, Lucas F. van Schaik, Daan van den Broek, , Gerrit A. Meijer, Iñaki Gutierrez Ibarluzea, Lorea Galnares Cordero, Remond J.A. Fijneman, Marjolijn J.L. Ligtenberg, Ed Schuuring, Wim H. van Harten, Veerle M.H. Coupé & Valesca P. Retèl (2025) - Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology - PharmacoEconomics - doi: 10.1007/s40273-025-01470-7 - [link]
- Lucas Frederik van Schaik, Ellen Gurumay Engelhardt, Wim Herbert van Harten & Valesca Pavlawna Retèl (2024) - Relevant factors for policy concerning comprehensive genomic profiling in oncology: stakeholder perspectives - BMC Cancer, 24 (1) - doi: 10.1186/s12885-024-13167-9 - [link]
- L. F. van Schaik, E. G. Engelhardt, E. A. Wilthagen, N. Steeghs, A. Fernández Coves, M. A. Joore, W. H. van Harten & V. P. Retèl (2024) - Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review - Critical Reviews in Oncology/Hematology, 202 - doi: 10.1016/j.critrevonc.2024.104441 - [link]
